{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:51:48Z","timestamp":1782345108972,"version":"3.54.5"},"reference-count":125,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaci.2017.02.013","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T14:26:26Z","timestamp":1488464786000},"page":"1445-1456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Biologic response modifiers: Indications, implications, and insights"],"prefix":"10.1016","volume":"139","author":[{"given":"Benjamin P.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair K.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.02.013_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2015.11.004","article-title":"The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects","volume":"137","author":"Grimbacher","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.jaci.2016.10.005","article-title":"Advances in clinical immunology in 2015","volume":"138","author":"Chinen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gut.2008.163683","article-title":"Dermatological complications and safety of anti-TNF treatments","volume":"58","author":"Kerbleski","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2017.02.013_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaci.2017.02.013_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/ACI.0b013e3283402b41","article-title":"Immunodeficiency secondary to anticytokine autoantibodies","volume":"10","author":"Browne","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib6","series-title":"Flu-like syndrome and cytokines. In: Cytokines in human health","first-page":"193","author":"Descotes","year":"2007"},{"key":"10.1016\/j.jaci.2017.02.013_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15476910801897433","article-title":"Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction","volume":"5","author":"Wing","year":"2008","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.jaci.2017.02.013_bib8","first-page":"873","article-title":"OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity","volume":"27","author":"Vasquez","year":"1995","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jaci.2017.02.013_bib9","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.02.013_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.jaci.2017.02.013_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/eci.09.31","article-title":"Monoclonal antibody-induced cytokine-release syndrome","volume":"5","author":"Bugelski","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/978-3-642-00663-0_16","article-title":"Mechanisms of adverse drug reactions to biologics","volume":"196","author":"Clarke","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jaci.2017.02.013_bib13","series-title":"Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies","first-page":"111","author":"H\u00fcnig","year":"2007"},{"key":"10.1016\/j.jaci.2017.02.013_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib16","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib18","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2017.02.013_bib19","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaci.2017.02.013_bib20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib21","article-title":"Cancer immunotherapy in patients with preexisting autoimmune disorders","author":"Donia","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2017.02.013_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-016-0434-0","article-title":"Cutaneous complications of targeted melanoma therapy","volume":"17","author":"de Golian","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jaci.2017.02.013_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/17512433.2016.1133289","article-title":"Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer","volume":"9","author":"Rossi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jaci.2017.02.013_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/sci.2016.09.13","article-title":"Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia\/lymphoma","volume":"3","author":"Fuji","year":"2016","journal-title":"Stem Cell Investig"},{"key":"10.1016\/j.jaci.2017.02.013_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cas.12617","article-title":"Recent advances in the treatment of adult T-cell leukemia-lymphomas","volume":"106","author":"Utsunomiya","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jaci.2017.02.013_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/imr.12272","article-title":"Inherited and acquired immunodeficiencies underlying tuberculosis in childhood","volume":"264","author":"Boisson-Dupuis","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2017.02.013_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2017.02.013_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2017.02.013_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","article-title":"Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial","volume":"39","author":"Igarashi","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib30","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.02.013_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2017.02.013_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2017.02.013_bib35","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/ajt.12460","article-title":"Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study","volume":"13","author":"Rostaing","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2017.02.013_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3747\/co.2007.118","article-title":"Hematology Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Alemtuzumab in chronic lymphocytic leukemia","volume":"14","author":"Fraser","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaci.2017.02.013_bib37","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2014incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.jaci.2017.02.013_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.02.013_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaci.2017.02.013_bib40","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jaci.2015.06.035","article-title":"Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab\u2014for how long?","volume":"136","author":"Barmettler","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1759720X15586782","article-title":"B-cell survival factors in autoimmune rheumatic disorders","volume":"7","author":"Morais","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib42","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib43","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jaci.2005.03.028","article-title":"Adverse reactions to biologic agents: focus on autoimmune disease therapies","volume":"116","author":"Lee","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2017.02.013_bib46","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamadermatol.2015.4992","article-title":"Perianal dermatophytosis during secukinumab therapy for plaque psoriasis","volume":"152","author":"Quach","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib48","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2017.02.013_bib49","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine"},{"key":"10.1016\/j.jaci.2017.02.013_bib51","doi-asserted-by":"crossref","first-page":"179180","DOI":"10.1155\/2014\/179180","article-title":"New onset of dermatomyositis\/polymyositis during anti-TNF-\u03b1 therapies: a systematic literature review","volume":"2014","author":"Brunasso","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.jaci.2017.02.013_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"St\u00fcbgen","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaci.2017.02.013_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semarthrit.2009.09.001","article-title":"Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk","volume":"40","author":"Khasnis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.02.013_bib54","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaci.2017.02.013_bib55","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.02.013_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib57","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.02.013_bib58","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/1097-0142(19900401)65:7<1521::AID-CNCR2820650712>3.0.CO;2-Y","article-title":"Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration","volume":"65","author":"Zukiwski","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2017.02.013_bib59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy","volume":"36","author":"Bessissow","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2017.02.013_bib60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000334805","article-title":"Eosinophilia during psoriasis treatment with TNF antagonists","volume":"223","author":"Malisiewicz","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2017.02.013_bib61","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1136\/annrheumdis-2011-200316","article-title":"Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study","volume":"70","author":"Schiff","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib62","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","author":"Colombel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2017.02.013_bib63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive Multifocal leukoencephalopathy and natalizumab\u2014unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib64","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients","volume":"57","author":"Fine","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib65","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: insights into integrin L 2 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2017.02.013_bib66","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.4049\/jimmunol.140.6.1883","article-title":"Endothelial activation during interleukin 2 immunotherapy. A\u00a0possible mechanism for the vascular leak syndrome","volume":"140","author":"Cotran","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib67","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.4049\/jimmunol.142.8.2660","article-title":"IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome","volume":"142","author":"Damle","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib68","unstructured":"IL-2 package insert. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103293s5130lbl.pdf. Accessed October 25, 2016."},{"key":"10.1016\/j.jaci.2017.02.013_bib69","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0009-9236(99)90083-8","article-title":"Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this \u201cadaptive response\u201d in mice","volume":"65","author":"Rakhit","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2017.02.013_bib70","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.02.013_bib71","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib72","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.02.013_bib73","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1126\/science.1128346","article-title":"Herpes simplex virus encephalitis in human UNC-93B deficiency","volume":"314","author":"Casrouge","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jaci.2017.02.013_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib75","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1586\/1744666X.2015.1077702","article-title":"Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome","volume":"11","author":"Kone-Paut","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib76","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib77","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.02.013_bib78","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.02.013_bib79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.smim.2014.09.008","article-title":"Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-\u03b3 immunity","volume":"26","author":"Bustamante","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib81","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib82","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.120906","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the Abatacept Clinical Trial Program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib83","first-page":"41","article-title":"A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations","volume":"8","author":"Wells","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.jaci.2017.02.013_bib84","series-title":"Cellular and molecular immunology","author":"Abbas","year":"2014"},{"key":"10.1016\/j.jaci.2017.02.013_bib85","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2017.02.013_bib86","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2017.02.013_bib87","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1\u2013neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib88","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor necrosis factor blockers: differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib89","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1469-0691.2006.01546.x","article-title":"Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections","volume":"12","author":"Moiton","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaci.2017.02.013_bib90","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.3748\/wjg.v17.i34.3881","article-title":"Current trends in management of hepatitis B virus reactivation in the biologic therapy era","volume":"17","author":"Mastroianni","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaci.2017.02.013_bib91","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/QCO.0b013e32832dda55","article-title":"Infectious complications of tumor necrosis factor blockade","volume":"22","author":"Wallis","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jaci.2017.02.013_bib92","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2017.02.013_bib93","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaci.2017.02.013_bib94","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.imbio.2013.04.021","article-title":"Primary complement C5 deficiencies\u2014Molecular characterization and clinical review of two families","volume":"218","author":"Schejbel","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaci.2017.02.013_bib95","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","article-title":"Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"165","author":"Wong","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.jaci.2017.02.013_bib96","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/17474086.2014.953926","article-title":"Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape","volume":"7","author":"Mastellos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jaci.2017.02.013_bib97","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis","volume":"172","author":"Blauvelt","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib98","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.02.013_bib99","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1185\/03007995.2015.1011778","article-title":"Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk","volume":"31","author":"Lebrec","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2017.02.013_bib101","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.amjmed.2010.11.028","article-title":"BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases","volume":"124","author":"Ramos-Casals","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib102","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2017.02.013_bib103","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents\u2014updated diagnosis, management, and treatment","volume":"3","author":"Galv\u00e3o","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2017.02.013_bib104","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1056\/NEJMc080834","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Arnold","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib105","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib106","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaci.2014.12.1947","article-title":"The alpha-gal story: Lessons learned from connecting the dots","volume":"135","author":"Steinke","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib107","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab)\u00a0treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib108","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 pathway in the liver: From physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaci.2017.02.013_bib109","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/08830185.2012.690794","article-title":"Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease","volume":"31","author":"Ghosh","year":"2012","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib110","article-title":"Idiopathic systemic capillary leak syndrome (Clarkson disease)","author":"Druey","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib111","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1189\/jlb.5RI0516-237RR","article-title":"STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases","volume":"101","author":"Lorenzini","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2017.02.013_bib113","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib114","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.alit.2016.04.011","article-title":"Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine","volume":"65","author":"Agache","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2017.02.013_bib115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.arbres.2014.02.002","article-title":"Future biologic therapies in asthma","volume":"50","author":"Quirce","year":"2014","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jaci.2017.02.013_bib116","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jaci.2007.10.028","article-title":"Targeting TNF-\u03b1: a novel therapeutic approach for asthma","volume":"121","author":"Brightling","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.02.013_bib117","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib118","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.02.013_bib120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2017.02.013_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/386148","article-title":"Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine","volume":"2014","author":"Da\u00efen","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaci.2017.02.013_bib122","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.semarthrit.2015.10.001","article-title":"Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","volume":"45","author":"Cantini","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaci.2017.02.013_bib123","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.gtc.2014.05.004","article-title":"Who should receive biologic therapy for IBD?","volume":"43","author":"Jones","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jaci.2017.02.013_bib124","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/apt.13736","article-title":"Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases","volume":"44","author":"Bek","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2017.02.013_bib125","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917303354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917303354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:05:43Z","timestamp":1758791143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917303354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0091674917303354"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.02.013","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic response modifiers: Indications, implications, and insights","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}